Promising Growth Stocks To Watch Now - December 29th

Prologis Stock Surges: Why the Rally May ContinuePrologis, Hamilton Lane, and Ascendis Pharma A/S are the three Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to increase revenues and earnings faster than the overall market, usually because of strong product demand, market expansion, or innovation. They often reinvest profits rather than pay dividends, trade at higher valuation multiples, and can offer substantial long-term capital appreciation but with greater volatility and risk. These companies had the highest dollar trading volume of any Growth stocks within the last several days.Prologis (PLD)Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.3 Dividend Stocks to Hold Through Market Volatility This FallRead Our Latest Research Report on PLDHamilton Lane (HLNE)Hamilton Lane Incorporated is a private equity firm specializing in early venture, emerging growth, turnaround, middle market, mature, mid-venture, bridge, buyout, distressed/vulture, loan, mezzanine in growth capital companies. It prefers to invest in energy, industrials, consumer discretionary, health care, real estate, information technology, utilities, and consumer services.3 Cloud Build-Out Stocks Behind the AI Infrastructure BoomRead Our Latest Research Report on HLNEAscendis Pharma A/S (ASND)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.Read Our Latest Research Report on ASNDSee AlsoMarketBeat's Top Five Stocks to Own in December 2025Broadcom's Insider Selling: A Big Red Flag, or Business as Usual?Verizon: Out of the Doghouse and Into Your Dividend Portfolio3 Picks-and-Shovels Ways to Invest in AI Without Betting on ChipmakersGold and Silver Are on Fire—These Canadian Miners Ride the WaveQualcomm Shares Are Back Near Their 2021 Price—Should Investors Be Worried or Excited?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Prologis Right Now?Before you consider Prologis, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prologis wasn't on the list.While Prologis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here